Late-stage trials of an advanced malaria vaccine candidate—which, if approved, would become the world’s first malaria vaccine—are under way. This article, published in Health Affairs, recounts the pivotal roles played by collaborations of nonprofit organizations, pharmaceutical companies, private and public donors, and countries whose citizens would benefit most directly from a vaccine.